ArticleGels (Basel, Switzerland)2025
Development of an Asymmetric Alginate Hydrogel Loaded with S-Nitrosoglutathione and Its Application in Chronic Wound Healing.
Article in Gels (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- The next generation of alginate dressings: recent innovations for chronic wound healing.Regenerative biomaterials · 2026Review
- Nitric Oxide-ReleasingPharmaceutics · 2025Article
- Advances in Preparation and Biomedical Applications of Sodium Alginate-Based Electrospun Nanofibers.Gels (Basel, Switzerland) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
Nitric oxide (NO) is an endogenous signaling molecule that plays a critical role in wound healing. However, the gaseous nature, short half-life, and low stability of NO present challenges for its clinical application. To address these issues, this study introduces an innovative S-nitrosoglutathione (GSNO)-loaded asymmetric alginate (SA) hydrogel (GSNO-SA) as a novel solution for treating infected chronic wounds. The hydrogel is designed with a layer-by-layer melting-permeation crosslinking approach, forming a dense upper layer and a sparse lower layer structure, effectively promoting exudate management while delaying NO release. The results demonstrate that the GSNO-SA hydrogel extends NO release for up to 48 h, exhibits rapid exudate absorption (72.3 ± 1.5% equilibrium swelling after 5 min), significant antibacterial activity (over 90% antibacterial rate against
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.